北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 风湿免疫科  > 期刊论文
学科主题: 临床医学
题名:
Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial
作者: Li Ting1; Chen Shun-le1; Dai Qing1; Han Xing-hai2; Li Zhan-guo3; Wu Dong-hai4; Zhang Xiao5; Gu Jie-ruo6; Yang Nan-ping7; Sun Ling-yun8; Zhang Miu-jia9; Li Xing-fu10; Bao Chun-de1
关键词: gout ; arthritis ; etoricoxib ; indometacin ; cyclooxygenase-2
刊名: CHINESE MEDICAL JOURNAL
发表日期: 2013-05-20
DOI: 10.3760/cma.j.issn.0366-6999.20122892
卷: 126, 期:10, 页:1867-1871
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: ORAL INDOMETHACIN ; CLINICAL-TRIAL ; CELECOXIB ; EFFICACY ; CYCLOOXYGENASE-2 ; MANAGEMENT ; DICLOFENAC ; OSTEOARTHRITIS ; ROFECOXIB ; INHIBITOR
英文摘要:

Background Acute gout is an intensely painful, inflammatory arthritis. Although the non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for this condition, the efficacy is based on only a few studies, particularly in China. We tried to assess the safety and efficacy of etoricoxib in the treatment of acute gouty arthritis in China.

Methods A randomized, double-blind, active comparator study was conducted at 10 sites in China. Patients (n=178; >= 18 years of age) with acute gouty attack (<48 hours) were treated for 5 days with etoricoxib (120 mg/d; n=89) or indometacin (75 mg twice daily; n=89). The primary efficacy end point was self-assessed pain in the affected joint (0-4 point Likert scale) from days 2-5. Secondary end points included investigator assessments of tenderness and swelling, patient/investigator global assessments of response to therapy, and patients discontinuing treatment. Safety was assessed by adverse events (AEs).

Results Etoricoxib and indometacin had comparable primary and secondary end points. Mean change difference from baseline from days 2-5 was 0.03 (95% confidence interval (CI) -0.19 to 0.25; P=0.6364), which fell within the prespecified comparative bounds of -0.5 to 0.5. No severe AEs were associated with etoricoxib use. Non-severe AEs were mainly digestive and general, and most (73.7%) were mild, although they caused withdrawal of two subjects in the etoricoxib group, due to bilateral renal calculi and uronephrosis of the left kidney (unrelated to etoricoxib) and fever and chills (potentially etoricoxib-related). Overall, AEs were similar, although the absolute number of AEs in the etoricoxib group (n=31) was less than the indometacin group (n=34).

Conclusions Etoricoxib (120 mg once daily) is effective in treating acute gout, is generally safe and well-tolerated, and is comparable in efficacy to indometacin (75 mg twice daily).

语种: 英语
项目资助者: Merck Sharp &amp ; Dohme, a subsidiary of Merck Company, Inc.
WOS记录号: WOS:000319529200013
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58509
Appears in Collections:北京大学第二临床医学院_风湿免疫科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, Shanghai 200001, Peoples R China
2.Changhai Hosp, Dept Rheumatol, Shanghai 200438, Peoples R China
3.Beijing Univ, Peoples Hosp, Dept Rheumatol, Beijing 100044, Peoples R China
4.China Japan Friendship Hosp, Dept Rheumatol, Beijing 100029, Peoples R China
5.Guangdong Prov Peoples Hosp, Dept Rheumatol, Guangzhou 510120, Guangdong, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol, Guangzhou 510630, Guangdong, Peoples R China
7.Sichuan Univ, West China Hosp, Dept Rheumatol, Chengdu 610041, Sichuan, Peoples R China
8.Nanjing Drum Tower Hosp, Dept Rheumatol, Nanjing 210008, Jiangsu, Peoples R China
9.Jiangsu Prov Hosp, Dept Rheumatol, Nanjing 210029, Jiangsu, Peoples R China
10.Qilu Hosp, Dept Rheumatol, Jinan 250012, Shandong, Peoples R China

Recommended Citation:
Li Ting,Chen Shun-le,Dai Qing,et al. Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial[J]. CHINESE MEDICAL JOURNAL,2013,126(10):1867-1871.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li Ting]'s Articles
[Chen Shun-le]'s Articles
[Dai Qing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li Ting]‘s Articles
[Chen Shun-le]‘s Articles
[Dai Qing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace